A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.

被引：0

作者：

Ishikawa, Mitsuya

Kitagawa, Ryo

Shibata, Taro

Tokunaga, Hideki

Iwata, Takashi

Nishio, Shin

Takada, Toshio

Mori, Masahiko

Horie, Koji

Kudaka, Wataru

Kagabu, Masahiro

Tanikawa, Michihiro

Kobayashi, Hiroaki

Yaegashi, Nobuo

机构：

[1] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan

[2] Moriya Daiichi Gen Hosp, Dept Gynecol & Obstet, Ibaraki, Japan

[3] Natl Canc Ctr, Operat Off, Japan Clin Oncol Grp Data Ctr, Tokyo, Japan

[4] Tohoku Univ Hosp, Dept Gynecol, Sendai, Miyagi, Japan

[5] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan

[6] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[7] Kitasato Univ, Dept Obstet & Gynecol, Sch Med, Sagamihara, Kanagawa, Japan

[8] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Aichi, Japan

[9] Saitama Canc Ctr, Dept Gynecol, Saitama, Japan

[10] Univ Ryukyus, Grad Sch Med Sci, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan

[11] Iwate Med Univ, Dept Obstet & Gynecol, Sch Med, Morioka, Iwate, Japan

[12] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan

[13] Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima, Japan

[14] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6027

引用

页数：2

共 50 条

[31] RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL COMPARED TO CARBOPLATIN-PACLITAXEL-TRASTUZUMAB IN ADVANCED (STAGE III-IV) OR RECURRENT UTERINE SEROUS CARCINOMA: RESULTS OF INTERIM ANALYSIS (NCT01367002)
Santin, A. D.
Fader, A. N.
Siegel, E.
Buza, N.
Pei, H.
Abdelghany, O.
Silasi, D. A.
Chambers, S.
Secord, A.
Havrilesky, L.
O'Malley, D. M.
Nevadunsky, N.
Edraki, B.
Pikaart, D.
Lowery, W.
ElSahwi, K.
Roque, D.
Schwartz, P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 873 - 874
[32] Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial
Downs, Levi S., Jr.
Chura, Justin C.
Argenta, Peter A.
Judson, Patricia L.
Ghebre, Rahel
Geller, Melissa A.
Carson, Linda F.
GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 265 - 269
[33] Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
Fleming, Nicole D.
Coleman, Robert L.
Tung, Celestine
Westin, Shannon N.
Hu, Wei
Sun, Yunjie
Bhosale, Priya
Munsell, Mark F.
Sood, Anil K.
GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 41 - 46
[34] Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial
Mittal, A.
Malik, P. S.
Kumar, S.
Saikia, J.
Chitikela, S.
Khurana, S.
Bharti, S.
Jain, D.
Pathy, S.
Thulkar, S.
Kumar, R.
Madan, K.
Mohan, A.
CLINICAL ONCOLOGY, 2021, 33 (12) : E553 - E560
[35] Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Semrad, Thomas John
Redman, Mary Weber
Herbst, Roy S.
Kim, Edward S.
Bazhenova, Lyudmila
Masters, Gregory A.
Oettel, Kurt R.
Guaglianone, Perry
Reynolds, Christopher M.
Karnad, Anand B.
Arnold, Susanne M.
Varella-Garcia, Marileila
Moon, James
Mack, Philip C.
Blanke, Charles David
Hirsch, Fred R.
Kelly, Karen
Gandara, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
Johnson, DH
Fehrenbacher, L
Novotny, WF
Herbst, RS
Nemunaitis, JJ
Jablons, DM
Langer, CJ
DeVore, RF
Gaudreault, J
Damico, LA
Holmgren, E
Kabbinavar, F
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191
[37] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
Shin Nishio
Ryo Kitagawa
Taro Shibata
Hiroyuki Yoshikawa
Ikuo Konishi
Kimio Ushijima
Toshiharu Kamura
Cancer Chemotherapy and Pharmacology, 2016, 78 : 785 - 790
[38] Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial
Ray-Coquard, Isabelle L.
Domont, Julien
Tresch-Bruneel, Emmanuelle
Bompas, Emmanuelle
Cassier, Philippe A.
Mir, Olivier
Piperno-Neumann, Sophie
Italiano, Antoine
Chevreau, Christine
Cupissol, Didier
Bertucci, Francois
Bay, Jacques-Olivier
Collard, Olivier
Saada-Bouzid, Esma
Isambert, Nicolas
Delcambre, Corinne
Clisant, Stephanie
Le Cesne, Axel
Blay, Jean-Yves
Penel, Nicolas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2797 - U116
[39] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
Nishio, Shin
Kitagawa, Ryo
Shibata, Taro
Yoshikawa, Hiroyuki
Konishi, Ikuo
Ushijima, Kimio
Kamura, Toshiharu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 785 - 790
[40] A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
Campos, Susana
Matulonis, Ursula
Berlin, Suzanne
Horowitz, Neil
Liu, Joyce
Krasner, Carolyn
Hang, Lee
Zarwan, Corrine
Barry, William
Colella, Tina
Whalen, Christen
Shoni, Melina
Lundquist, Christine
Birrer, Michael J.
Penson, Richard
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1881 - 1890

← 1 2 3 4 5 →